$SUND
Sundance Strategies, Inc. Stock $sund

$sund Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-Q Financial Statement

#000101041214000019 Filed on February 14, 2014

Income Statement

Concept	2014 Q1	2013 Q4	2013 Q2
Revenue	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$920.0K	$350.0K	$1.030M
YoY Change	1214.29%	1650.0%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$70.00K	$354.4K	$1.034M
YoY Change	-28.63%	2129.43%	29312.94%
Operating Profit		-$354.4K	-$1.034M
YoY Change		2129.43%	29312.94%
Interest Expense	-$20.00K	$31.02K	$30.07K
YoY Change	-404.09%	47623.08%	46166.15%
% of Operating Profit
Other Income/Expense, Net	-$850.0K	$1.646M	-$30.05K
YoY Change	12823.83%	-2532121.54%	46133.85%
Pretax Income	-$90.00K	$1.291M	-$1.064M
YoY Change	-14.0%	-6556.9%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$90.00K	$1.291M	-$1.064M
YoY Change	-14.0%	-8189.83%	29618.35%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.966K	$30.53K	-$25.68K
COMMON SHARES
Basic Shares Outstanding	42.92M shares	42.26M shares	40.80M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013 Q4	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$380.0K	$120.0K	$1.260M
YoY Change	-30.91%
Cash & Equivalents	$375.2K	$124.9K	$1.259M
Short-Term Investments
Other Short-Term Assets	$0.00
YoY Change
Inventory
Prepaid Expenses	$2.000K
Receivables
Other Receivables
Total Short-Term Assets	$377.2K	$124.9K	$1.259M
YoY Change	-30.84%	34970.22%	607884.06%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$15.83M	$14.87M	$12.10M
YoY Change	151.27%
Other Assets	$3.585M	$8.573M	$8.573M
YoY Change
Total Long-Term Assets	$16.70M	$15.74M	$12.10M
YoY Change	165.17%
TOTAL ASSETS
Total Short-Term Assets	$377.2K	$124.9K	$1.259M
Total Long-Term Assets	$16.70M	$15.74M	$12.10M
Total Assets	$17.08M	$15.86M	$13.36M
YoY Change	149.55%	4455667.42%	6451700.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$52.92K	$21.12K	$250.0K
YoY Change	-40.6%	82.88%	64835.06%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$3.000M
YoY Change	-100.0%
Long-Term Debt Due	$90.00K	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$142.9K	$28.57K	$3.253M
YoY Change	-95.38%	-27.62%	16691.56%
LONG-TERM LIABILITIES
Long-Term Debt	$1.460M	$1.430M	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$1.460M	$1.425M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$142.9K	$28.57K	$3.253M
Total Long-Term Liabilities	$1.460M	$1.425M	$0.00
Total Liabilities	$1.599M	$1.454M	$3.253M
YoY Change	-48.35%	3583.63%	16691.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$310.8K	-$218.7K	-$1.169M
YoY Change	196.98%	-58.59%	129.96%
Common Stock	$15.09M	$3.315M	$11.28M
YoY Change	36896.23%	88058.54%	99871.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.48M	$14.41M	$10.10M
YoY Change
Total Liabilities & Shareholders Equity	$17.08M	$15.86M	$13.36M
YoY Change	149.55%	4455667.42%	6451700.48%

Cashflow Statement

Concept	2014 Q1	2013 Q4	2013 Q2
OPERATING ACTIVITIES
Net Income	-$90.00K	$1.291M	-$1.064M
YoY Change	-14.0%	-8189.83%	29618.35%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$870.0K	-$2.450M	-$6.239M
YoY Change	-73.82%		124923.35%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$860.0K
YoY Change
Cash From Investing Activities	$0.00	-$860.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$6.952M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.120M	2.460M	$6.952M
YoY Change	-71.05%		140339.9%
NET CHANGE
Cash From Operating Activities	-870.0K	-2.450M	-$6.239M
Cash From Investing Activities	0.000	-860.0K
Cash From Financing Activities	1.120M	2.460M	$6.952M
Net Change In Cash	250.0K	-850.0K	$713.1K
YoY Change	-54.16%		-1782875.0%
FREE CASH FLOW
Cash From Operating Activities	-$870.0K	-$2.450M	-$6.239M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001171838
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42915941	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	Sundance Strategies, Inc.
CY2013Q4	sund	Advance To Consultant For Services AdvanceToConsultantForServices	25000	USD
CY2013Q4	sund	Capitalized Consultant Fee CapitalizedConsultantFee	300000	USD
CY2013Q4	sund	Face Value Of Net Insurance Benefits Purchased Under Asset Transfer Agreement FaceValueOfNetInsuranceBenefitsPurchasedUnderAssetTransferAgreement	400000000	USD
CY2013Q2	sund	Face Value Of Net Insurance Benefits Purchased Under Asset Transfer Agreement FaceValueOfNetInsuranceBenefitsPurchasedUnderAssetTransferAgreement	400000000	USD
	sund	Fair Value Of Warrants Issued Stock Issuance Costs FairValueOfWarrantsIssuedStockIssuanceCosts	139521	USD
	sund	Fair Value Of Warrants Issued Stock Issuance Costs FairValueOfWarrantsIssuedStockIssuanceCosts	139251	USD
	sund	Life Insurance Policies Purchased With Debt LifeInsurancePoliciesPurchasedWithDebt		USD
	sund	Life Insurance Policies Purchased With Debt LifeInsurancePoliciesPurchasedWithDebt	2999000	USD
CY2013Q4	sund	Life Settlement Contracts Investment Method Expenses Plus Interest In Next Twelve Months LifeSettlementContractsInvestmentMethodExpensesPlusInterestInNextTwelveMonths	2138350	USD
CY2013Q4	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid After Year Five LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidAfterYearFive	11093150	USD
CY2013Q4	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Five LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearFive	2757670	USD
CY2013Q4	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Four LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearFour	2578870	USD
CY2013Q4	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Three LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearThree	3102811	USD
CY2013Q4	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Two LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearTwo	3846568	USD
CY2013Q4	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid Total LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidTotal	25517419	USD
	sund	Life Settlement Contracts Investment Method Premiums Paid And Other Expenses LifeSettlementContractsInvestmentMethodPremiumsPaidAndOtherExpenses	23786079	USD
CY2013Q4	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaid	64770785	USD
CY2013Q4	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid After Year Five LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidAfterYearFive	29532166	USD
CY2013Q4	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Next Twelve Months LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInNextTwelveMonths	6291750	USD
CY2013Q4	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Five LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearFive	6892281	USD
CY2013Q4	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Four LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearFour	6326361	USD
CY2013Q4	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Three LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearThree	7386359	USD
CY2013Q4	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Two LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearTwo	8341868	USD
CY2013Q1	sund	Life Settlement Contracts Portion Of Pledge Agreement Paid In Cash LifeSettlementContractsPortionOfPledgeAgreementPaidInCash	3000000	USD
CY2013Q1	sund	Life Settlement Contracts Purchased Through Pledge Agreement LifeSettlementContractsPurchasedThroughPledgeAgreement	5999000	USD
CY2013Q4	sund	Maximum Number Of Common Shares Offered Through Private Placement MaximumNumberOfCommonSharesOfferedThroughPrivatePlacement	3000000	shares
CY2013Q2	sund	Maximum Number Of Common Shares Offered Through Private Placement MaximumNumberOfCommonSharesOfferedThroughPrivatePlacement	3000000	shares
	sund	Number Of Shares Of Restricted Stock Sold Through Private Placement NumberOfSharesOfRestrictedStockSoldThroughPrivatePlacement	2118500	shares
CY2013Q4	sund	Return Of Premium Provisions On Life Settlement Contracts ReturnOfPremiumProvisionsOnLifeSettlementContracts	384801	USD
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled Or Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledOrExpiredInPeriodIntrinsicValue		USD
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms	P1Y4M28D
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageRemainingContractualTerms
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms	P2Y
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Intrinsic Value Extended ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValueExtended		USD
CY2013Q4	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedOutstandingWeightedAverageExercisePrice	5.00
CY2013Q1	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedOutstandingWeightedAverageExercisePrice
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceForfeitures
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceGranted	5.00
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice	5.00
	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue		pure
	sund	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm2
	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresWeightedAverageGrantDateFairValue		pure
	sund	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2	P5Y
CY2013Q4	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	0.97	pure
CY2013Q1	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue		pure
CY2013Q4	sund	Structuring And Consulting Agreement Terms StructuringAndConsultingAgreementTerms	In the event the Qualified NIBs delivered are less than $300,000,000 in face value under the DMF Agreement, Del Mar and Europa shall be jointly and severally liable for liquidated damages equal to the aggregate of the cash payment under the Del Mar ATA and all of the costs advanced, reduced by the pro rata percentage of the Qualified NIBs delivered and accepted by SSI, multiplied by two; and if at least $300,000,000 in Qualified NIBs are delivered and accepted, then the cash payment and all costs will not be doubled if they are paid within 90 days.
CY2013Q2	sund	Structuring And Consulting Agreement Terms StructuringAndConsultingAgreementTerms	The Company is required to pay a structuring fee of 1% of the face amount of the life insurance policies underlying all NIBs introduced and acquired, payable as follows: 50% of the fee on the delivery of the NIBs; and the remaining 50% being payable on the conversion of the NIBs to Qualified NIBs as defined in the Del Mar ATA.
CY2013Q4	sund	Total Cash Consideration That Would Be Paid By Company If All Net Insurance Benefits Are Provided Under Asset Transfer Agreement TotalCashConsiderationThatWouldBePaidByCompanyIfAllNetInsuranceBenefitsAreProvidedUnderAssetTransferAgreement	12000000	USD
CY2013Q2	sund	Total Cash Consideration That Would Be Paid By Company If All Net Insurance Benefits Are Provided Under Asset Transfer Agreement TotalCashConsiderationThatWouldBePaidByCompanyIfAllNetInsuranceBenefitsAreProvidedUnderAssetTransferAgreement	8000000	USD
CY2013Q2	sund	Total Consideration That Would Be Paid By Company If All Net Insurance Benefits Are Provided Under Asset Transfer Agreement TotalConsiderationThatWouldBePaidByCompanyIfAllNetInsuranceBenefitsAreProvidedUnderAssetTransferAgreement	20000000	USD
CY2013Q2	sund	Total Notes Payable That Would Be Issued By Company If All Net Insurance Benefits Are Provided Under Asset Transfer Agreement TotalNotesPayableThatWouldBeIssuedByCompanyIfAllNetInsuranceBenefitsAreProvidedUnderAssetTransferAgreement	12000000	USD
CY2013Q4	sund	Working Capital WorkingCapital	96285	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	21124	USD
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	89082	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11318393	USD
CY2013Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3850257	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3272500	USD
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock		USD
CY2013Q4	us-gaap	Assets Assets	15862532	USD
CY2013Q1	us-gaap	Assets Assets	6844417	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	124850	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	545417	USD
CY2013Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	15737682	USD
CY2013Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	6299000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	124850	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	545417	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-420567	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	124850	USD
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	5.00
CY2013Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	70000	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42261411	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40797441	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42261441	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40797441	shares
CY2013Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	3272500	USD
CY2013Q4	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	654500	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	42261	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	40798	USD
CY2013Q1	us-gaap	Debt Instrument Collateral DebtInstrumentCollateral	50% of the NIBs
CY2013Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2999000	USD
CY2013Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.02	pure
CY2013Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P2Y
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="WIDTH: 660px"><!--StartFragment--> <p style="MARGIN: 0px; text-align: justify"><strong>(2) NEW ACCOUNTING PRONOUNCEMENTS</strong></p> <p style="MARGIN: 0px; text-align: justify"><br /> </p> <p style="MARGIN: 0px; text-align: justify; TEXT-INDENT: 48px">The Company has reviewed recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.</p> <!--EndFragment--></div> </div>
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.03
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M17D
CY2013Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1243548	USD
	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	5.00
CY2013Q2	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	5.00
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1672124	USD
CY2013Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1672124	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1672124	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1355526	USD
CY2013Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	253770	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1409428	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-114055	USD
CY2013Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1291380	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-218706	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid		USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2013Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-61382	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	13370	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	4710	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	4710	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	91802	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	98378	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	8572972	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	8572972	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3300000	USD
	us-gaap	Interest Expense InterestExpense	91802	USD
CY2013Q4	us-gaap	Interest Expense InterestExpense	31020	USD
	us-gaap	Interest Expense InterestExpense	98379	USD
	us-gaap	Interest Income Other InterestIncomeOther	4731	USD
CY2013Q4	us-gaap	Interest Income Other InterestIncomeOther	4710	USD
	us-gaap	Interest Income Other InterestIncomeOther	4731	USD
	us-gaap	Interest Paid InterestPaid		USD
	us-gaap	Interest Paid InterestPaid		USD
CY2013Q4	us-gaap	Interest Receivable InterestReceivable	4710	USD
CY2013Q1	us-gaap	Interest Receivable InterestReceivable		USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	18938	USD
CY2013Q4	us-gaap	Liabilities Liabilities	1453819	USD
CY2013Q1	us-gaap	Liabilities Liabilities	3095523	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15862532	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6844417	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1		USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	15195	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28565	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3095523	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1425254	USD
CY2013Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		USD
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	6299000	USD
CY2013Q1	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	6299000	USD
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	129423734	USD
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing After Year Five LifeSettlementContractsInvestmentMethodFaceValueMaturingAfterYearFive	113423734	USD
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodFaceValueMaturingInNextTwelveMonths		USD
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Five LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFive	6000000	USD
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Four LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFour	10000000	USD
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Three LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearThree		USD
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Two LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearTwo		USD
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Five Year Disclosure Premiums To Be Paid LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid	39253366	USD
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	22	pure
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing After Year Five LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingAfterYearFive	18	pure
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInNextTwelveMonths	0	pure
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Five LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFive	3	pure
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Four LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFour	1	pure
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Three LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearThree	0	pure
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Two LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearTwo	0	pure
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid After Year Five LifeSettlementContractsInvestmentMethodPremiumsToBePaidAfterYearFive	18439016	USD
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Next Twelve Months LifeSettlementContractsInvestmentMethodPremiumsToBePaidInNextTwelveMonths	4153400	USD
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Five LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFive	4134611	USD
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Four LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFour	3747491	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1699108	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-354434	USD
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Three LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearThree	4283548	USD
CY2013Q4	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Two LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearTwo	4495300	USD
CY2013Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1425254	USD
CY2013Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable		USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	10037875	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	13906615	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-861000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-861000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9597442	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12920765	USD
	us-gaap	Net Income Loss NetIncomeLoss	-114055	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	1291380	USD
	us-gaap	Net Income Loss NetIncomeLoss	-218706	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1585053	USD
CY2013Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1645814	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1578476	USD
CY2013Q4	us-gaap	Notes Payable Current NotesPayableCurrent		USD
CY2013Q1	us-gaap	Notes Payable Current NotesPayableCurrent	2999000	USD
CY2013Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	3441	USD
CY2013Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	3441	USD
CY2013Q4	us-gaap	Notes Receivable Net NotesReceivableNet	861000	USD
CY2013Q1	us-gaap	Notes Receivable Net NotesReceivableNet		USD
	us-gaap	Operating Expenses OperatingExpenses	1699108	USD
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	354434	USD
	us-gaap	Operating Expenses OperatingExpenses	1797182	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1797182	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8572972	USD
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	586400	USD
CY2013Q2	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	24000000	USD
CY2013Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		USD
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8572972	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4000	USD
CY2013Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4000	USD
CY2013Q2	us-gaap	Other Notes Payable OtherNotesPayable	12000000	USD
	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	861000	USD
	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	861000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6765375	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10634115	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10592500	USD
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	3272500	USD
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	3272500	USD
	us-gaap	Professional Fees ProfessionalFees	343582	USD
CY2013Q4	us-gaap	Professional Fees ProfessionalFees	100664	USD
	us-gaap	Professional Fees ProfessionalFees	387754	USD
CY2013Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	5735	USD
CY2013Q1	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	37510	USD
CY2013Q2	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	4000000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-218706	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104651	USD
	us-gaap	Revenues Revenues		USD
CY2013Q4	us-gaap	Revenues Revenues		USD
	us-gaap	Revenues Revenues		USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y4M10D
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1656338	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1072500	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	735999	USD
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		USD
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested		USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	70000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.92
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.92
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P1Y4M28D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	70000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.92
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	70000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1.54
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y4M10D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	3374450
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2185000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.97
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3374450	USD
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2185000	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.54
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.97
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.54
CY2013Q1	us-gaap	Share Price SharePrice	5.00
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	14408713	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	3748894	USD
	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1	37510	USD
	us-gaap	Stock Issued During Period Shares Issued For Cash StockIssuedDuringPeriodSharesIssuedForCash	1464000	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	654500	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	7320000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3272500	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	735999	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	735999	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41490857	shares
CY2013Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42261441	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted		shares

Files In Submission

Name	View Source	Status
0001010412-14-000019-index-headers.html	Edgar Link	pending
0001010412-14-000019-index.html	Edgar Link	pending
0001010412-14-000019.txt	Edgar Link	pending
0001010412-14-000019-xbrl.zip	Edgar Link	pending
ex311.htm	Edgar Link	pending
ex312.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
qtr31231138lwbclean.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sund-20131231.xml	Edgar Link	completed
sund-20131231.xsd	Edgar Link	pending
sund-20131231_cal.xml	Edgar Link	unprocessable
sund-20131231_def.xml	Edgar Link	unprocessable
sund-20131231_lab.xml	Edgar Link	unprocessable
sund-20131231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SUND
Sundance Strategies, Inc. Stock $sund

2014 Q1 Form 10-Q Financial Statement

#000101041214000019 Filed on February 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUND Sundance Strategies, Inc. Stock $sund

2014 Q1 Form 10-Q Financial Statement

#000101041214000019 Filed on February 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUND
Sundance Strategies, Inc. Stock $sund